Video

Anti-PD-1 Treatment Selection

During this segment, Richard W. Joseph, MD, describes the effectiveness of the anti-PD-1 agents pembrolizumab and nivolumab, and discusses similarities and differences between the 2 drugs.

Dr Joseph explains that although no head-to-head trials have directly compared the 2 agents, cross-trial comparisons have demonstrated that they are similar in terms of safety and efficacy. For this reason, he questions why the FDA approved pembrolizumab after just a phase 1 study but required a phase 3 study prior to approving nivolumab.

One difference between the 2 drugs, he notes, is that while nivolumab is administered every 2 weeks, pembrolizumab is given every 3 weeks.

Dr Joseph suggests that unless proved otherwise, the agents should be considered equivalent by managed care organizations and payer coverage should be the same for both drugs.


Related Videos
A panel of 4 experts on PDTs
A panel of 4 experts on PDTs
A panel of 5 experts on Alzheimer disease
A panel of 5 experts on Alzheimer disease
Video 2 - "SunRISe-1: Examining Combination Therapy for HR NMIBC"
Video 1 - "Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC "
Ravin Ratan, MD, MEd, MD Anderson
Dr Migvis Monduy
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Paul Frohna, MD, PhD, PharmD.
Related Content
CH LogoCenter for Biosimilars Logo